

Pro-Mapp Software for Managing Orthopaedic Care Pathway


Pro-Mapp is a software enabled system for orthopaedic care pathway management, implant safety monitoring, and patient reported outcome delivery.

Pro-Mapp is a new spinout venture originating from research collaboration between Oxford University researchers and expert health care software collaborators, Fr3dom Limited. It is currently seeking first round investment of \$900,000 to be followed with \$2-4m in 9 to 12 months' time, and a third round likely at 3 years.

Pro-Mapp is a software enabled system for orthopaedic care pathway management, implant safety monitoring, and patient reported outcome delivery. The orthopaedic implant industry is worth over \$6bn per year and the founding board members include world leading clinicians and academics.

There are three initial revenue and business channels:

- Joint Access is a clinical pathway system that uses patient reported outcome measures (PROMS) intelligently to support clinical pathway management of hip, knee and shoulder procedures.



- SSAFE is a long term surveillance system that allows large scale post-operative surveillance at a cost previously inaccessible to implant manufacturers.
- Fr3PROMS is a tool that can be used to distribute, monetise if necessary, and present PROM tools and shared decision making tools (SDMs) digitally. It does not own or create content, but is a delivery system. Fr3proms already carries content for all mandated procedures in England as well as a large number of tools for other organisations including the Kettering Cancer Centre, New York and iOutcomes for the Oxford Scores.



Revenue will be generated through sales of SSAFE and Joint Access to manufacturers and large hospitals, clinics and high volume surgeons. Fr3proms is distributed and bought online, giving immediate market accessibility. Users of Fr3proms may upgrade to Joint Access on the unified software platform. This is further enhanced by the links with SSAFE allowing primary, secondary and follow up care to access the same information when a patient is consented.

The platform is now fully developed and ready for field testing and scale up in different environments and countries. Customers already include Zimmer, Biomet (SSAFE), Oxford University Hospitals (Joint Access) NHS Scotland and SITU the surgical trials unit at Oxford.



Professor David Beard
Musculoskeletal Sciences, NDORMS
University of Oxford
david.beard@ndorms.ox.ac.uk



Mr Toby Knightley-Day
Managing Director, Fr3dom Ltd
toby@fr3dom.net

